ALGORAE PHARMACEUTICALS ORD
Algorae Pharmaceuticals Advances Commercial Pathway as AI Platform Validation and Distribution Agreements Gather Pace
Algorae Pharmaceuticals (ASX: 1AI) advances AlgoraeOS validation and signs Dr Reddy's distribution, signals near-term oncology revenue and stronger balance sheet.
Algorae Pharmaceuticals Identifies 90 New Drug-Combination Candidates from AlgoraeOS V2 Analysis
Algorae Pharmaceuticals (ASX: 1AI) has identified 90 high-quality drug-combination candidates following a preliminary review of newly delivered in silico synergy predictions generated by its upgraded AlgoraeOS v2 platform.
Algorae Pharmaceuticals Achieves Independent Validation of AlgoraeOS and Launches Enhanced v2 Platform
Algorae Pharmaceuticals (ASX: 1AI) has reported independent preclinical validation of its AlgoraeOS v1 drug-combination prediction platform following a major study at the Victorian Centre for Functional Genomics at the Peter MacCallum Cancer Centre.
Algorae Pharmaceuticals to Partner with Dr Reddy’s for Australian Supply of Chemotherapy Medicine
Algorae Pharmaceuticals (ASX: 1AI) has signed a distribution partnership with Indian multinational Dr Reddy’s Laboratories to supply chemotherapy medicine capecitabine to the Australian market.
